ITM Gets Fast Track for Radiopharmaceutical Treatment for Neuroendocrine Tumors
ITM Isotope Technologies Munich has received FDA’s Fast Track designation for ITM-11, an investigational radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors.
ITM-11 consists of two components—the medical radioisotope lutetium-177 and a targeting molecule edotreotide, a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors.
The targeted therapy delivers radiation directly to destroy tumor tissue while minimizing radiation exposure to normal tissue.
The FDA’s Fast Track process is designed to expedite the review of drugs to treat serious conditions and fill an unmet medical need.